Standout Papers

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: ... 2021 2026 2022 2024203
  1. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study (2021)
    Martin Hutchings, Rogier Mous et al. The Lancet

Immediate Impact

60 standout
Sub-graph 1 of 21

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
8 intermediate papers

Works of Dena DeMarco being referenced

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
2021 Standout
Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data
2020
and 1 more

Author Peers

Author Last Decade Papers Cites
Dena DeMarco 289 96 37 217 13 329
Andy Chen 201 34 57 111 20 257
Michelle Poon 241 20 25 200 16 310
M Andreeff 132 64 88 134 14 367
Simon Corbett 293 159 95 78 12 359
Yngvild Nuvin Blaker 202 14 31 170 12 286
Lia Palomba 160 55 12 224 14 279
Jan Oliver Staak 164 64 54 216 13 339
Lauren Mauro 274 17 80 149 12 369
Alexander Z. Wei 116 100 60 88 18 303
Vittoria Tarantino 147 114 18 255 12 340

All Works

Loading papers...

Rankless by CCL
2026